Invitae Hereditary Lymphoma Panel
Use
The Invitae Hereditary Lymphoma Panel analyzes genes associated with hereditary susceptibility to lymphoma. This testing is designed to confirm clinical diagnosis, predict disease prognosis, facilitate early detection, inform family planning, and potentially enroll patients in clinical trials. It is specifically for heritable germline mutations and not suitable for somatic mutation detection.
Special Instructions
If a patient has undergone an allogeneic bone marrow or stem cell transplant or currently has hematological conditions with actively circulating tumor cells, a non-blood sample type like cultured fibroblasts from a skin biopsy is recommended. Contact Invitae Clinical team for further assistance.
Limitations
Analytical sensitivity and specificity exceed 99% for single nucleotide variants and small insertions/deletions. Detection of larger insertions/deletions, structural rearrangements, and variants in difficult-to-sequence regions may be less reliable. Detection of mosaicism or phasing of variants is not guaranteed. Non-coding regions and certain complex rearrangements are not analyzed.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
10-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
3mL
Minimum Volume
Not provided
Container
purple-top EDTA tube (K2EDTA or K3EDTA)